Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 26 Issue 11, November 2020

Volume 26 Issue 11

iPSC-derived cells for patients with GvHD

Conventional mesenchymal stromal cell (MSC)-based manufacturing approaches are hampered by challenges with scalability and inter-donor variability, which leads to inconsistent results from diverse clinical trials. Novel induced pluripotent stem cell (iPSC)-based techniques have the potential to overcome these challenges by facilitating the clinical-grade production of very large quantities of consistently differentiated cells. This illustration by Patton'd Studios represents an iPSC-derived mesenchymoangioblast colony, which is a crucial intermediate step in an optimized good manufacturing practice–compliant process for MSC production.

See Rasko and colleagues

Image credit: Patton'd Studios. Cover design: Erin Dewalt.


News Feature

Turning Points

  • Turning Points |

    Kizzmekia ‘Kizzy’ Corbett, a viral immunologist and research fellow, is the team lead for coronavirus research within the Viral Pathogenesis Laboratory of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health.

    • Kizzmekia Corbett


World View


  • Comment |

    The limitations of using race in biomedicine are important to recognize because race is often afforded more biological value than can be scientifically justified — and less social value than it commands.

    • George Adigbli

Research Highlights

News & Views

Brief Communications

  • Brief Communication |

    The durability of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. Lessons from seasonal coronavirus infections in humans show that reinfections can occur within 12 months of initial infection, coupled with changes in levels of virus-specific antibodies.

    • Arthur W. D. Edridge
    • , Joanna Kaczorowska
    •  & Lia van der Hoek



Amendments & Corrections


Quick links